SightGlass Vision reports successful myopia control in children using DOT spectacle lenses
Click Here to Manage Email Alerts
SightGlass Vision has announced positive results from its 4-year CYPRESS study, which tested myopia control performance of the company’s Diffusion Optics Technology spectacle lenses.
According to a company press release, the DOT 0.2 lenses use thousands of light-scattering elements called dots, which are designed to mimic more natural contrast on the retina and slow myopia progression in children.
Image: Adobe Stock
The CYPRESS study was conducted in two parts: The first was a 36-month, multicenter, randomized trial assessing the safety and efficacy of DOT lenses vs. control lenses in 256 children aged 6 to 10 years with myopia. The second part re-enrolled 98 participants to collect an additional 12 months of data.
According to the release, study results demonstrated statistically significant slowing of axial length progression and cycloplegic spherical equivalent refraction (cSER) after 4 years. During the 36- to 48-month timeframe, axial length mean change was 0.13 mm for the test group (n = 55) and 0.18 mm for the control group (n = 41; P = 0.038), with a cSER mean change of –0.25 D and –0.38 D, respectively (P = 0.043).
“The CYPRESS 4-year findings confirm the demonstrated efficacy, safety and overall performance of Diffusion Optics Technology spectacle lenses,” Andrew Sedgwick, SightGlass CEO, said in the release. “Eye care professionals worldwide are demanding this level of scientific rigor, allowing them to confidently recommend the lenses to children and their caregivers. SightGlass Vision is proud to advance the myopia control category with our latest research and technologies, and enthusiastic about growing opportunities for spectacles in a child’s treatment regimen.”
Reference:
- Rappon J, et al. Br J Ophthalmol. 2022;doi:10.1136/bjo-2021-321005.
Read more about
Click Here to Manage Email Alerts